revamilast   Click here for help

GtoPdb Ligand ID: 9865

Synonyms: Example 26 [WO2006064355A2] | GRC 4039 | GRC-4039 | GRC4039
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Revamilast (GRC 4039) is an orally active, selective phosphodiesterase IV (PDE4) inhibitor, that was developed by Glenmark Pharmaceuticals for the treatment of multiple inflammatory conditions (rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (COPD) , multiple sclerosis, osteoarthritis, neuropathic pain). The chemical structure is claimed as Example 26 in Glenmark patent WO2006064355A2 [1]. GRC 4039 is no longer listed on Glenmark's development pipeline webpage.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 89.85
Molecular weight 438.99
XLogP 4.13
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES FC(Oc1ccc(c2c1oc1c2cncc1)C(=O)N=c1c(Cl)cn(cc1Cl)O)F
Isomeric SMILES FC(Oc1ccc(c2c1oc1c2cncc1)C(=O)N=c1c(Cl)cn(cc1Cl)O)F
InChI InChI=1S/C18H9Cl2F2N3O4/c19-10-6-25(27)7-11(20)15(10)24-17(26)8-1-2-13(29-18(21)22)16-14(8)9-5-23-4-3-12(9)28-16/h1-7,18,27H
InChI Key CFRXVFRHMZLQBS-UHFFFAOYSA-N
Bioactivity Comments
We have assigned the IC50 value for revamilast obtained from patent WO2006064355A2 to PDE4A, but the assay description in the patent document does not specify the isozyme tested, or the source of the PDE4 used [1].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
phosphodiesterase 4A Hs Inhibitor Inhibition 8.6 pIC50 - 1
pIC50 8.6 (IC50 2.69x10-9 M) [1]